The downgrade is based on several factors, including MCHD’s significant concentration in mineral values resulting in assessed values that are estimated to fall between fiscal year 2015 and 2017.
The outlook is negative, reflecting Moody’s Investors Services expectation of a 22 percent decline in MCHD’s revenue due to the tax base contraction.
More articles on healthcare finance:
Baystate Health asks for $10M to save 200 jobs
Maine hospital to stop outpatient addiction services
Baker Tilly partner appointed to HFMA Principles and Practices Board: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
